chemical 구조를 spider web으로

Cleavable and non-cleavable linker scaffolds used across auristatin, maytansinoid, and TOP1 ADCs.

Aminopyridine scaffold to crizotinib, alectinib, brigatinib, lorlatinib.

Carboxamide and tricyclic pharmacophores — levetiracetam, carbamazepine, lamotrigine.

BH3-mimetic scaffold to venetoclax, navitoclax, sonrotoclax and SAR analogs.

Phenylaminopyrimidine core to imatinib, nilotinib, dasatinib, ponatinib.

1,4-Benzodiazepine core to diazepam, lorazepam and midazolam anxiolytics / sedatives.

Chloro-aryl pharmacophore to vemurafenib, dabrafenib, trametinib, cobimetinib.

Ibrutinib, acalabrutinib, zanubrutinib and covalent BTK warhead analogs.

Enediyne warhead for gemtuzumab ozogamicin (Mylotarg) and related ADCs.

Pyrrolopyrimidine core to palbociclib, ribociclib, abemaciclib and derivatives.

Cholinesterase and NMDA pharmacophores — donepezil, rivastigmine, memantine.

KRAS G12C covalent inhibitor core and derived small molecules, ADC payloads, linkers, and assembled ADCs.

Maytansine-derived microtubule inhibitors — DM1 and DM4 used in Kadcyla and related ADCs.

Cyclopropapyrroloindole (CPI) DNA-alkylator payloads for ADCs — duocarmycin SA and seco forms.

Quinazoline / aminopyrimidine core to 1st-gen drugs and 3rd-gen osimertinib (Tagrisso) with resistance mutations.

Camptothecin-derived TOP1 inhibitor payloads — DXd powers Enhertu and related ADC platforms.

Pyrrolopyrimidine JAK hinge core to approved JAK1/2/3 inhibitors.

Shared acrylicamide / warhead chemotype from core scaffold to sotorasib, adagrasib, daraxonrasib and SAR analogs.

Non-covalent and RAS(ON) chemotypes targeting KRAS G12D — MRTX1133, RMC-6236, RMC-9805 and SAR analogs.

Microtubule-disrupting auristatin payloads derived from dolastatin 10 — widely used in approved and clinical ADCs.

Nicotinamide mimic pharmacophore to olaparib, niraparib, rucaparib and talazoparib.

Pyrrolobenzodiazepine dimers — SG3199, tesirine payloads for hematologic ADCs.

Morpholino-pyrimidine PI3K pharmacophore to isoform-selective PI3K, AKT, and mTOR inhibitors.

Bifunctional degrader scaffold with E3-ligase recruiter motifs — AR, ER, BTK, BRD4 and KRAS PROTACs.

Multi-kinase hinge pharmacophore spanning selective RET, MET, and NTRK inhibitors.

Camptothecin analog prodrug irinotecan → active SN-38; foundation for many TOP1 ADC payloads.

Aryloxy-propylamine pharmacophore from fluoxetine and sertraline to escitalopram and venlafaxine.

Paclitaxel core to docetaxel, cabazitaxel and semisynthetic analogs.